HSF1 is involved in immunotherapeutic response through regulating APOJ/STAT3-mediated PD-L1 expression in hepatocellular carcinoma-Reference-Cited by-同舟云学术

HSF1 is involved in immunotherapeutic response through regulating APOJ/STAT3-mediated PD-L1 expression in hepatocellular carcinoma

Published:2022-12-08 Issue:1 Volume:24 Page:1-9
ISSN:1538-4047
Container-title:Cancer Biology & Therapy
language:en
Short-container-title:Cancer Biology & Therapy

Author:

Cheng Hongxia¹,Wang Sikai¹,Huang Aidan¹²,Ma Jing¹,Gao Dongmei¹,Li Miaomiao¹,Chen Huaping³,Guo Kun¹^ORCID

Affiliation:

1. Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion Ministry of Education, Shanghai, People’s Republic of China

2. Guangxi Zhuang Autonomous Region Women and Children Care Hospital, Guangxi, China

3. Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University Nanning, Guangxi, China

Funder

National Natural Science Foundation of China

Publisher

Informa UK Limited

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/15384047.2022.2156242

Reference55 articles.

1. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance

2. Immune checkpoint inhibitors for hepatocellular carcinoma

3. UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma

4. Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer

5. Comprehensive transcriptome profiling in elderly cancer patients reveals aging‐altered immune cells and immune checkpoints

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AGR2: The Covert Driver and New Dawn of Hepatobiliary and Pancreatic Cancer Treatment;Biomolecules;2024-06-23

2. Exploring Natural Compounds Targeting PD-L1 and STAT3: Toxicogenomic Analysis, Virtual Screening, Molecular Docking, ADMET Evaluation, and Biological Activity Prediction;Current Computer-Aided Drug Design;2024-05-28

3. The current status and future of PD-L1 in liver cancer;Frontiers in Immunology;2023-12-12

4. The tumour-promoting role of protein homeostasis: Implications for cancer immunotherapy;Cancer Letters;2023-10

5. Ginsenoside Rh4 inhibits breast cancer growth through targeting histone deacetylase 2 to regulate immune microenvironment and apoptosis;Bioorganic Chemistry;2023-06